Jan Kuhlmann Andersen, Ph.D., M.Sc. Biology/Immunology, joins BioPorto A/S (BioPorto) on September 12, 2016 as Chief Operation Officer (COO). As a consequence and on the same date, he will retire from the Board of Directors of BioPorto for which he was elected in 2015. Jan Kuhlmann Andersen comes from a position as Vice President at Chr. Hansen A/S with global responsibility for sales and marketing in Animal Health & Nutrition. Jan Kuhlmann Andersen replaces Michael Pålsson as COO.
Peter M. Eriksen, CEO of BioPorto, commented: "Jan Kuhlmann Andersen has great insight into BioPorto and our industry, and with a strong background from a global market leader he will be a major operational asset for BioPorto."
The Executive Management of BioPorto is still constituted by Peter M. Eriksen, while the Board of Directors now consists of Thomas Magnussen (chairman), Torben A. Nielsen (Vice Chairman) and Niels Christian Nielsen
For further information, please contact:
Peter M. Eriksen, CEO, Telephone +45 4529 0034, e-mail investor@bioporto.com
Gry Husby Larsen, General Counsel, Telephone +45 4094 1543
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ Copenhagen stock Exchange.
